[Skip to Content]
Upstate University Hospital

Research Studies

 

Home-Spirometry through Telemedicine in ALS

A study measuring the use of home-spirometry compared to hospital-based spirometry for accuracy and efficacy in measuring respiratory decline using telemedicine.

Site PI: Dr. Eufrosina Young
Study Coordinator: Lena Deb (DebL@upstate.edu; 315-464-9756)
ClinicalTrials.gov Identifier: NCT05106569

Currently Recruiting

MT-1186-A04

A Phase 3b, Multi-center, Randomized, Double-blind study to evaluate efficacy and safety of Oral Edaravone Administered for a Period of 48 weeks in Subjects with ALS
A study measuring the use of oral Edaravone, the oral form of the FDA-approved medication Edaravone (Radicava ©) in patients with ALS

Site PI: Dr. Eufrosina Young
Study Coordinator: Sigiriya Smolen (SmolenS@upstate.edu; 315-464-9767)
ClinicalTrials.gov Identifier: NCT04569084

Currently Recruiting

HEALEY ALS Platform Trial

This is the first ALS platform trial, accelerating the path to new ALS therapies by testing multiple treatments at once, reducing the cost of research by 30%, decreasing the trial time by 50% and increasing patient participation by 67%

Site PI: Dr. E. Young
Study Coordinator: Lena Deb (DebL@upstate.edu; 315-464-9756)
ClinicalTrials.gov Identifier: NCT04297683

Currently Recruiting for Regimen E only

COMBAT- ALS

A phase 2b/3 Multi-center, Randomized, Double-blind, placebo-controlled, 12 month clinical trial to evaluate the efficacy and safety of MN-166 (ibudilast) followed by an open-label extension in subjects with ALS.

A study measuring the safety and efficacy of Ibudilast (MN-166) for use in ALS. This drug has already shown promise in ALS in its phase 2 trial in improving patient’s functional activity, quality of life and muscle strength.

Site PI: Dr. Jenny Meyer
Study Coordinator: Sigiriya Smolen (SmolenS@upstate.edu; 315-464-9767)
ClinicalTrials.gov Identifier: NCT04057898

Currently Recruiting

COURAGE-ALS

A Phase 3, Multi-Center, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with ALS.

Reldesemtiv acts on your muscles to strengthen contraction. Reldesemtiv has been tested in humans extensively and it showed promise in an earlier ALS trial. During the second half of the study, all patients will receive the active drug.

Site PI: Dr. Deborah Bradshaw
Study Coordinator: Sigiriya Smolen (SmolenS@upstate.edu; 315-464-9767)
ClinicalTrials.gov Identifier: NCT04944784

Currently Recruiting

Top